IBC 293 is a cell permeable Niacin triazolo derivative that is a selective agonist towards the human orphan G-protein-coupled receptor GPR109b/HM74. In addition, IBC 293 inhibits forskolin (sc-3562) and isoproterenol (sc-202188) in GPR109b-expressing CHO cells and human adipocytes. The inhibition of forskolin and isoproterenol also causes a reduction in cAMP levels in both cell lines. It has been reported that GPR 109b occurs as homodimers and heterodimers in which the extent of homo-dimerization and hetero-dimerization does not depend on ligand binding.
1. Mandrika, I., et al. 2010. Biochem. Biophys. Res. Commun. 395: 281-287. PMID: 20380810
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.